Hydroxyurea (Synonyms: 羥基脲; Hydroxycarbamide)

目錄號: HY-B0313 純度: 99.34%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

Hydroxyurea 通過抑制核糖核苷酸還原酶抑制 DNA 合成的細(xì)胞凋亡誘導(dǎo)劑。Hydroxyurea 具有抗正痘病毒活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Hydroxyurea Chemical Structure

CAS No. : 127-07-1

1. 客戶無需承擔(dān)相應(yīng)的運輸費用。

2. 同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥400	In-stock
1 g	￥500	In-stock
5 g	￥650	In-stock
10 g		詢價
50 g		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

Other Forms of Hydroxyurea:

Hydroxyurea (Standard) 詢價

MCE 顧客使用本產(chǎn)品發(fā)表的 16 篇科研文獻(xiàn)

•Signal Transduct Target Ther. 2022 Oct 17;7(1):354. [Abstract]
•Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]
•ACS Nano. 2023 Sep 14. [Abstract]
•Cell Death Differ. 2023 Feb 7. [Abstract]
•Nat Commun. 2022 Aug 16;13(1):4822. [Abstract]
•Proc Natl Acad Sci U S A. 2023 May 16;120(20):e2303479120. [Abstract]

•Cell Death Dis. 2020 Nov 12;11(11):976. [Abstract]
•Cell Death Dis. 2020 Jun 15;11(6):464. [Abstract]
•Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
•J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
•J Cell Mol Med. 2019 Oct;23(10):6797-6804. [Abstract]
•J Biol Chem. 2023 Jun 28;104984. [Abstract]
•Arch Biochem Biophys. 2020 Nov 15;694:108601. [Abstract]
•Res Sq. 2024 Jul 02.
•bioRxiv. 2023 Dec 5.
•Holistic Integrative Oncology. 13 October 2022.

: Hydroxyurea purchased from MCE. Usage Cited in: Cell Death Differ. 2023 Feb 7. [Abstract]; The interaction between MARVELD1 and PARP1 is greatly enhanced following exposure to Hydroxyurea (HU) in HeLa (8?mM HU; 24 h) and HEK293T cells (4?mM HU; 24 h).

Hydroxyurea 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 HIV 亞型特異性產(chǎn)品:

查看所有亞型

HIV HIV-1 HIV-2

生物活性
實驗參考方法
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase. Hydroxyurea shows anti-orthopoxvirus activity.

IC₅₀ & Target

HIV-1

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
Erythrocyte	CC₅₀	147 μM Compound: HU	Cytotoxicity against human erythrocytes assessed as cell viability after 3 days alamar blue assay Cytotoxicity against human erythrocytes assessed as cell viability after 3 days alamar blue assay	[PMID: 33109398]
HeLa S3	ED₅₀	1.96 μg/mL Compound: hydroxyurea	Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
K562	IC₅₀	687.94 μM Compound: Hydroxyurea	Cytotoxicity against Homo sapiens (human) K562 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells after 24 hr by MTT assay	10.1007/s00044-010-9544-6
KB	ED₅₀	5.29 μg/mL Compound: hydroxyurea	Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
L1210	ED₅₀	2.67 μg/mL Compound: hydroxyurea	Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
L1210	IC₅₀	82 μM Compound: Hydroxyurea	Activity against lymphocytic murine leukemia cell line L1210 using MTS/PES microculture tetrazolium assay Activity against lymphocytic murine leukemia cell line L1210 using MTS/PES microculture tetrazolium assay	[PMID: 11784145]
MOLT-3	ED₅₀	3.18 μg/mL Compound: hydroxyurea	Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
SW480	ED₅₀	4.79 μg/mL Compound: hydroxyurea	Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
U373-MAGI	EC₅₀	25.8 μM Compound: Hydroxyurea	Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas	[PMID: 27117260]
U373-MAGI	CC₅₀	252 μM Compound: Hydroxyurea	Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM) Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)	[PMID: 27117260]
U-937	IC₅₀	115 μM Compound: Hydroxyurea	Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay	10.1007/s00044-011-9778-y
Vero	IC₅₀	0.1 mM Compound: Hydroxyurea (HU)	Compound tested on vero cells infected with Toxoplasma gondii after 24 h Compound tested on vero cells infected with Toxoplasma gondii after 24 h	[PMID: 15863319]
Vero	IC₅₀	0.1 mM Compound: Hydroxyurea (HU)	Compound tested on intracellular parasites Toxoplasma gondii in vero cells after 24 h Compound tested on intracellular parasites Toxoplasma gondii in vero cells after 24 h	[PMID: 15863319]

體外研究
(In Vitro)

Hydroxyurea 用于許多骨髓增生性疾病、腫瘤、HIV 和非血液疾病的研究^[1]。
用 30 μM Hydroxyurea 處理原代培養(yǎng)物中的細(xì)胞 96 小時可顯著增加部分 HbF 含量。^Gγ:^Aγ-珠蛋白 mRNA 在體外誘導(dǎo) 0.30 至 8 倍. Hydroxyurea 已被證明可以阻斷靜止的外周血單核細(xì)胞和巨噬細(xì)胞中的 HIV-1 逆轉(zhuǎn)錄和/或復(fù)制^[2]^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Hydroxyurea 療法在 17 周內(nèi)持續(xù)降低 WBC 和 ANC，但貧血沒有改善。與賦形劑處理的鐮狀細(xì)胞小鼠相比，50 mg/kg 的 Hydroxyurea 可降低白細(xì)胞計數(shù)和中性粒細(xì)胞絕對計數(shù)，并且貧血沒有改善^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

76.05

Formula

CH₄N₂O₂

CAS 號

127-07-1

性狀

固體

顏色

White to off-white

中文名稱

羥基脲

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性數(shù)據(jù)

細(xì)胞實驗：

H₂O 中的溶解度 : 50 mg/mL (657.46 mM; 超聲助溶)

DMSO 中的溶解度 : 50 mg/mL (657.46 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	13.1492 mL	65.7462 mL	131.4924 mL
5 mM	2.6298 mL	13.1492 mL	26.2985 mL
10 mM	1.3149 mL	6.5746 mL	13.1492 mL

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據(jù)您的實驗動物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (32.87 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (32.87 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (32.87 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

方案一

請依序添加每種溶劑： PBS
Solubility: 100 mg/mL (1314.92 mM); 澄清溶液; 超聲助溶

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實驗過程有損耗，建議您多配一只動物的量

計算結(jié)果

工作液所需濃度 : mg/mL

該產(chǎn)品水溶性佳，請具體參考實測水 / PBS / Saline 中的溶解度數(shù)據(jù)。

您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。

純度 & 產(chǎn)品資料

純度: 99.34%

選擇批次：

Data Sheet (641 KB) SDS (418 KB)

COA (282 KB) HNMR (125 KB) RP-HPLC (260 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31. [Content Brief]

[2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92. [Content Brief]

[3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7. [Content Brief]

[4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603. [Content Brief]

[5]. M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60(2):506-14. [Content Brief]

Animal Administration ^[4]	Mice: To determine whether hydroxyurea would improve anemia and/or prevent or diminish the development of organ damage in the absence of HbF induction, hydroxyurea, at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, or vehicle is administered five days per week to SCD mice^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)	[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31. [Content Brief] [2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92. [Content Brief] [3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7. [Content Brief] [4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603. [Content Brief] [5]. M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60(2):506-14. [Content Brief]

Animal Administration
^[4]

Mice: To determine whether hydroxyurea would improve anemia and/or prevent or diminish the development of organ damage in the absence of HbF induction, hydroxyurea, at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, or vehicle is administered five days per week to SCD mice^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻(xiàn)

[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31. [Content Brief]

[2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92. [Content Brief]

[3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7. [Content Brief]

[4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603. [Content Brief]

[5]. M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60(2):506-14. [Content Brief]

Hydroxyurea 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	13.1492 mL	65.7462 mL	131.4924 mL	328.7311 mL
	5 mM	2.6298 mL	13.1492 mL	26.2985 mL	65.7462 mL
	10 mM	1.3149 mL	6.5746 mL	13.1492 mL	32.8731 mL
	15 mM	0.8766 mL	4.3831 mL	8.7662 mL	21.9154 mL
	20 mM	0.6575 mL	3.2873 mL	6.5746 mL	16.4366 mL
	25 mM	0.5260 mL	2.6298 mL	5.2597 mL	13.1492 mL
	30 mM	0.4383 mL	2.1915 mL	4.3831 mL	10.9577 mL
	40 mM	0.3287 mL	1.6437 mL	3.2873 mL	8.2183 mL
	50 mM	0.2630 mL	1.3149 mL	2.6298 mL	6.5746 mL
	60 mM	0.2192 mL	1.0958 mL	2.1915 mL	5.4789 mL
	80 mM	0.1644 mL	0.8218 mL	1.6437 mL	4.1091 mL
	100 mM	0.1315 mL	0.6575 mL	1.3149 mL	3.2873 mL

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Hydroxyurea127-07-1Hydroxycarbamide羥基脲DNA/RNA SynthesisAutophagyApoptosisHIVOrthopoxvirusHuman immunodeficiency virusInhibitorinhibitorinhibit

您最近查看的產(chǎn)品:

產(chǎn)品名稱：

* 需求量：

* 客戶姓名：

* Email：

* 電話：

* 公司或機構(gòu)名稱：

留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只為有資質(zhì)的科研機構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。

站點地圖隱私聲明

滬ICP備15051369號-4

上海工商

滬公網(wǎng)安備31011502019417

滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS)

營業(yè)執(zhí)照（三證合一）

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Hydroxyurea (Synonyms: 羥基脲; Hydroxycarbamide)

Customer Review

Other Forms of Hydroxyurea:

MCE 顧客使用本產(chǎn)品發(fā)表的 16 篇科研文獻(xiàn)